Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 08/08/2017

Debbie Rigby rounds up the latest in research news Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease Analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial provides more evidence of the renoprotective effects of SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

because much of the time, I think they’re giving antibiotics for things that are not UTIsPolitician says "I think" and…

Michael Hewson

Medics to ‘fight’ Doctor of Pharmacy title

Yet right now there are far too many reports from overseas of patients being unsure whether their care is from…

Michael Hewson

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan

Research Roundup

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.